MR ASAP

Multicentre Randomised trial of Acute Stroke treatment in the Ambulance with a nitroglycerin Patch

MR ASAP is part of the Collaboration for New Treatments of Acute Stroke. The CONTRAST consortium aims to improve outcome in stroke patients by merging translational research and pragmatic randomised clinical trials. 

In MR ASAP, we will determine the effect of prehospital transdermal nitroglycerin, given within 3 hours of stroke onset, on functional outcome at 90 days in patients with acute ischaemic stroke or intracerebral haemorrhage. Trained paramedics from ± 10 ambulance regions in the Netherlands will recruit a total of 1400 patients.